TNFRSF21;DR6;UNQ437/PRO868

Tumor necrosis factor receptor superfamily member 21 (Death receptor 6) (CD antigen CD358)

Homo sapiens (Human)

71845

655

Pending Verification

Tumor necrosis factor receptor superfamily member 21 (Death receptor 6) (CD antigen CD358)

N/A

MUTAGEN 82 82 N->Q: Abolishes one glycosylation site and reduces total N-glycosylation; when associated with Q-252; Q-278 and Q-289. {ECO:0000269|PubMed:19654028}.; MUTAGEN 141 141 N->Q: Abolishes one glycosylation site and reduces total N-glycosylation; when associated with Q-82; Q-252; Q-278 and Q-289. {ECO:0000269|PubMed:19654028}.; MUTAGEN 252 252 N->Q: Abolishes one glycosylation site and reduces total N-glycosylation; when associated with Q-278 and Q-289. {ECO:0000269|PubMed:19654028}.; MUTAGEN 257 257 N->Q: Abolishes one glycosylation site and reduces total N-glycosylation; when associated with Q-82; Q-141; Q-252; Q-278 and Q-289. {ECO:0000269|PubMed:19654028}.; MUTAGEN 278 278 N->Q: Abolishes one glycosylation site and reduces total N-glycosylation. Abolishes one glycosylation site and reduces total N-glycosylation; when associated with Q-82; Q-141; Q-252; Q-257 and Q-289. {ECO:0000269|PubMed:19654028}.; MUTAGEN 289 289 N->Q: Abolishes one glycosylation site and reduces total N-glycosylation; when associated with Q-278. {ECO:0000269|PubMed:19654028}.; MUTAGEN 368 368 C->V: Abolishes palmitoylation.

MGTSPSSSTALASCSRIARRATATMIAGSLLLLGFLSTTTAQPEQKASNLIGTYRHVDRATGQVLTCDKCPAGTYVSEHCTNTSLRVCSSCPVGTFTRHENGIEKCHDCSQPCPWPMIEKLPCAALTDRECTCPPGMFQSNATCAPHTVCPVGWGVRKKGTETEDVRCKQCARGTFSDVPSSVMKCKAYTDCLSQNLVVIKPGTKETDNVCGTLPSFSSSTSPSPGTAIFPRPEHMETHEVPSSTYVPKGMNSTESNSSASVRPKVLSSIQEGTVPDNTSSARGKEDVNKTLPNLQVVNHQQGPHHRHILKLLPSMEATGGEKSSTPIKGPKRGHPRQNLHKHFDINEHLPWMIVLFLLLVLVVIVVCSIRKSSRTLKKGPRQDPSAIVEKAGLKKSMTPTQNREKWIYYCNGHGIDILKLVAAQVGSQWKDIYQFLCNASEREVAAFSNGYTADHERAYAALQHWTIRGPEASLAQLISALRQHRRNDVVEKIRGLMEDTTQLETDKLALPMSPSPLSPSPIPSPNAKLENSALLTVEPSPQDKNKGFFVDESEPLLRCDSTSSGSSALSRNGSFITKEKKDTVLRQVRLDPCDLQPIFDDMLHFLNPEELRVIEEIPQAEDKLDRLFEIIGVKSQEASQTLLDSVYSHLPDLL

Promotes apoptosis, possibly via a pathway that involves the activation of NF-kappa-B. Can also promote apoptosis mediated by BAX and by the release of cytochrome c from the mitochondria into the cytoplasm. Plays a role in neuronal apoptosis, including apoptosis in response to amyloid peptides derived from APP, and is required for both normal cell body death and axonal pruning. Trophic-factor deprivation triggers the cleavage of surface APP by beta-secretase to release sAPP-beta which is further cleaved to release an N-terminal fragment of APP (N-APP). N-APP binds TNFRSF21; this triggers caspase activation and degeneration of both neuronal cell bodies (via caspase-3) and axons (via caspase-6). Negatively regulates oligodendrocyte survival, maturation and myelination. Plays a role in signaling cascades triggered by stimulation of T-cell receptors, in the adaptive immune response and in the regulation of T-cell differentiation and proliferation. Negatively regulates T-cell responses and the release of cytokines such as IL4, IL5, IL10, IL13 and IFNG by Th2 cells. Negatively regulates the production of IgG, IgM and IgM in response to antigens. May inhibit the activation of JNK in response to T-cell stimulation. {ECO:0000269|PubMed:21725297, ECO:0000269|PubMed:22761420, ECO:0000269|PubMed:9714541}.

Beta strand (18); Chain (1); Disulfide bond (9); Domain (1); Erroneous initiation (1); Glycosylation (6); Helix (7); Lipidation (1); Mutagenesis (7); Repeat (4); Signal peptide (1); Topological domain (2); Transmembrane (1); Turn (1); Up-regulated by TNF. {ECO:0000269|PubMed:19654028, ECO:0000269|PubMed:23559013}.; Detected in fetal spinal cord and in brain neurons, with higher levels in brain from Alzheimer disease patients (at protein level). Highly expressed in heart, brain, placenta, pancreas, lymph node, thymus and prostate. Detected at lower levels in lung, skeletal muscle, kidney, testis, uterus, small intestine, colon, spleen, bone marrow and fetal liver. Very low levels were found in adult liver and peripheral blood leukocytes. {ECO:0000269|PubMed:21725297, ECO:0000269|PubMed:23559013, ECO:0000269|PubMed:9714541}.

Tumor necrosis factor receptor superfamily member 21 (Death receptor 6) (CD antigen CD358)

Recombinant

HEK293

Lyophilized

7.4-7.5

Sterile-filtered colorless solution

1mg/ml

Standard

PBS

SDS-PAGE

> 98%

RP-HPLC

-20°C

This bioreagent is stable at 4°C (short-term) and -70°C(long-term). After reconstitution, sample may be stored at 4°C for 2-7 days and below -18°C for future use.

Reconstitute in sterile distilled H2O to no less than 100ug/ml; dilute reconstituted stock further in other aqueous solutions if needed. Please review COA for lot-specific instructions. Final measurements should be determined by the end-user for optimal performance.